POA POS. Its all the same at gsk.
The VBU is all gsk has when talking about innovation. Shingrix sales will reach saturation in the next 18 months, the rsv vaccine will boost sales and will encounter stiff competition.
That's it folks. Sure the new ABCWY single shot will cement men sales and that's about it. Oncology is a turd sinking fast. Respiratory, a turd sinking fast. Biologics, a turd sinking fast.
Just sell the divisions off and get rid of sales management which has to be the worst in the industry.